Clinical trial
Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory…
NCT00286091 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00286091 |
|---|---|
| Title | Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer |
| Intervention type | Biological |
| Interventions | Denosumab, Placebo |
| Enrollment | 1,435 |
| Start date | Jan 24, 2006 |
| Primary completion | Jul 30, 2010 |
| Completion | Apr 9, 2014 |
| First posted | Feb 3, 2006 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: